Edition:
United States

Natalie Grover

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Oct 05 2017

Elderly with dementia at risk for inappropriate medications

(Reuters Health) - More than half of elderly patients with dementia are prescribed at least one potentially inappropriate medication, a recent study from eight European countries suggests.

Aug 30 2017

Otonomy pulls plug on ear drug, shares nosedive

Otonomy Inc said on Wednesday it suspended developing its drug for Meniere's disease, a chronic disorder of the inner ear, after it failed a late-stage trial, sending the drugmaker's shares plummeting in premarket trade.

Aug 28 2017

Drugmakers tackle 'ick' factor with fecal transplant therapies

The seventh time Catherine Duff contracted C. diff, a debilitating infection of the gut, she did not respond to antibiotics. She believes her life was saved by a transplant of her husband's feces.

Aug 28 2017

Gilead to buy Kite for promising cancer therapies in $12 billion deal

Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.

Aug 24 2017

Adamas Pharma secures approval for Parkinson's dyskinesia drug

The U.S. Food and Drug Administration (FDA) said it had approved Adamas Pharmaceuticals Inc's treatment for a side effect caused by a commonly prescribed Parkinson's drug, sending the shares of the drugmaker soaring in after-market trading.

Aug 07 2017

Zynerba shares plunge as cannabis-based epilepsy gel fails study

Zynerba Pharmaceuticals Inc's stock lost more than half its value on Monday after the U.S. drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage study.

Aug 04 2017

Lilly's acute migraine drug succeeds in late-stage study

Drugmaker Eli Lilly and Co said on Friday its acute migraine drug lasmiditan succeeded in a key late-stage study, setting the stage for U.S. regulatory approval.

Aug 03 2017

Regeneron beats profit view, to end antibody deal with Sanofi

Regeneron Pharmaceuticals Inc reported a much better-than-expected quarterly profit on strong demand for its flagship Eylea drug and said it would end one of its agreements with France's Sanofi SA to develop antibodies by the end of the year.

Aug 02 2017

Illumina shares sparkle on strong demand for new gene tech

Shares of Illumina Inc surged nearly 14 percent on Wednesday, a day after the company raised its 2017 revenue forecast on strong demand for its new gene-sequencing technology.

Aug 01 2017

Pfizer delays major M&A as it awaits U.S. tax reform clarity

Pfizer Inc's chief executive said on Tuesday he would prefer to wait for clarity on U.S. tax reform before engaging in any big deals in order to get a better understanding of any potential acquisition target's value. | Video

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary